TMX Newsfile Health News Releases

DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis

Thu, 10 Sep 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, is pleased to announce positive final results from its clinical study conducted with AlyaTec for TeaRx™ Red Eye further to the Company's press releases dated December 2, 2025, February 26, 2026, and July 9, 2026.The final results were obtained and analysed from 93 tear samples originating from...

Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate

Thu, 10 Sep 2026 07:55:00 -0400

Filament Health has begun planning a stability program for IBEX011, its naturally derived botanical ibogaine drug candidate, in response to growing demand for GMP quality, standardized ibogaine for clinical research.Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned...

MD Hyperbaric Appoints Renowned Hyperbaric Researcher Dr. Amir Hadanny as Chief Medical Officer

Wed, 09 Sep 2026 09:00:00 -0400

New York, New York--(Newsfile Corp. - September 9, 2026) - MD Hyperbaric, one of the fastest-growing hyperbaric oxygen therapy (HBOT) networks in the United States, announced the appointment of Amir Hadanny, MD, as Chief Medical Officer. Dr. Hadanny is a neurosurgeon and hyperbaric physician and one of the most published clinical researchers in hyperbaric medicine, with more than 80 peer-reviewed publications.In this role, Dr. Hadanny will lead all clinical activity across MD Hyperbaric's...

LevelJump Announces Management Change

Wed, 09 Sep 2026 08:37:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") wishes to announce the appointment of Gus Patel as the Company's interim Chief Financial Officer effective September 1, 2026, replacing Robert Landau.Gus Patel is a finance executive, tax practitioner and licensed public accountant with more than 15 years of experience across public companies, private enterprises and professional services. His experience includes...

QScreen AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Wed, 09 Sep 2026 06:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 9, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the final tranche of its previously announced non-brokered private placement.The Company is pleased to announce that it has completed the final tranche of its previously announced non-brokered private placement...

WELL Health Announces Planned CFO Transition; Evelyn Sutherland Appointed Chief Financial Officer

Wed, 09 Sep 2026 06:00:00 -0400

WELL has appointed Evelyn Sutherland as Chief Financial Officer, effective September 21, 2026. Ms. Sutherland brings more than 20 years of senior financial leadership experience, including CFO roles at Staples Canada, Enercare Inc., KEYreit, and United Purchasing Group of Canada (Yum! Brands).Ms. Sutherland has served on the Board of WELL's subsidiary, WELLSTAR, over the past year and brings direct knowledge of the Company's strategy, governance and culture to the role.Eva Fong, WELL's...

Nasdaq Shareholder Requirements Just Verified By Adia Med

Tue, 08 Sep 2026 08:00:00 -0400

Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes:At least 300 round-lot holders;A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; andAdia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.Nasdaq Shareholder...

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes Shipment of PEX010 to Australia for University of Melbourne Trial of Psilocybin-Assisted Physiotherapy in Functional Neurological Disorder

Tue, 08 Sep 2026 07:52:00 -0400

Filament Health's patented, naturally derived psilocybin drug candidate PEX010 has been shipped to Austin Health in Melbourne for PSI-PHY, an investigator initiated pilot trial of psilocybin-assisted physiotherapy in refractory motor functional neurological disorder, sponsored by The University of Melbourne and funded by the Australian Government's Medical Research Future FundThe study is the first trial of PEX010 in a movement disorder and, to the Company's knowledge, the first anywhere to...

Altrova Health Signs Exclusive U.S. Distribution Agreement to Launch Its Detection and Wellness Portfolio Across the United States

Tue, 08 Sep 2026 07:07:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 8, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that it has entered into an exclusive distribution agreement (the "Distribution Agreement") with Reliability Funding LLC ("Reliability" or the "Distributor") appointing Reliability as the Company's exclusive sales agent and distributor for its product portfolio across the entire United States. The Distribution Agreement...

WELL Health Announces WELLTRUST(TM) Surpasses 100,000 Patient Consents

Tue, 08 Sep 2026 06:30:00 -0400

WELLTRUST™, a WELL-managed database of consented WELL patients, has surpassed 100,000 patient consents since launching in February 2026. Every consent represents a patient who has expressly agreed to be contacted about clinical trials and research studies matched to their health circumstances. HEALWELL's DARWEN™ AI platform is used to connect WELLTRUST™ patients with life sciences companies, including pharma and biotech trial sponsors and Contract Research Organizations (CROs), by matching trial...